CP
SUPN icon

Camelot Portfolios’s Supernus Pharmaceuticals SUPN Stock Holding History

Camelot Portfolios’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$5.35K – 503
2024
Q2 		$5.35K Buy
+200
New +$5.8K ﹤0.01% 469

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Camelot Portfolios's SUPN Position: Q3 2024 in Review

Camelot Portfolios sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 200 shares — an estimated $5.35K sold.

Camelot Portfolios first reported a position in SUPN in Q2 2024 and held it in 1 quarter. The position peaked at $5.35K in Q2 2024. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

  • Camelot Portfolios reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Camelot Portfolios sold 200 Supernus Pharmaceuticals shares in Q3 2024, an estimated $5.35K.
  • Camelot Portfolios first reported a position in Supernus Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Camelot Portfolios's Supernus Pharmaceuticals position peaked at $5.35K in Q2 2024.
  • 273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on Camelot Portfolios's 13F filing for Q3 2024, filed 12 Nov 2024.